MRNAModerna Inc
Company Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Bullish
68
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Interest & Investment Income
Other Income / (Expense), net
Total Other Income / (Expense), net
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/ACompany Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Bullish
68
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Interest & Investment Income
Other Income / (Expense), net
Total Other Income / (Expense), net
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/AUpcoming Earnings
Company Info
CEO
Stéphane Bancel
Location
Massachusetts, USA
Exchange
Nasdaq
Website
https://modernatx.com
Summary
Moderna, Inc.
Company Info
CEO
Stéphane Bancel
Location
Massachusetts, USA
Exchange
Nasdaq
Website
https://modernatx.com
Summary
Moderna, Inc.
Community Research
Research from investors like you
Be the first to share your analysis on MRNA
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.
Symbol's posts
Markets Pull Back, but Some Stocks Are Still Showing Strength
Markets Pull Back, but Some Stocks Are Still Showing Strength
Dow Jones futures slipping after a rebound in the S&P 500 and Nasdaq is a reminder that this market can change direction quickly. I’m keeping an eye on individual setups rather than assuming the whole market will move together. Moderna , AMD , and SpaceX-related momentum are worth watching, but I’d still want to see follow-through before getting too confident. A stock flashing a buy signal is one thing; holding those gains is another. Are you finding any opportunities in this market, or waiting for a clearer trend?
Wall Street Is Catching Its Breath, but Tech Still Looks Shaky
Wall Street Is Catching Its Breath, but Tech Still Looks Shaky
Stock futures holding steady doesn’t necessarily mean the market is out of trouble. After a rough session for tech, investors are trying to figure out whether this is just a temporary pullback or the start of something bigger. Moderna took a heavy hit after news around its cancer vaccine data, while concerns over AI spending are putting pressure on companies like Meta . I’m watching earnings closely because strong results may not be enough if investors start questioning valuations. Do you think this dip is a buying opportunity, or is it better to wait for more clarity?
Markets Are Getting Hit, and Moderna Is Feeling the Pain
Markets Are Getting Hit, and Moderna Is Feeling the Pain
The market feels pretty unsettled right now. Moderna took a sharp hit after cancer vaccine data leaked earlier than expected, while Meta added to the pressure on tech stocks as investors questioned its heavy AI spending. What stands out to me is how quickly sentiment can shift when expectations get too high. I’m watching whether this weakness spreads further or creates opportunities in companies with stronger fundamentals. Are you buying this dip or staying on the sidelines for now?
BioNTech revenue down 60%, hit with recent clinical trial setbacks
BioNTech revenue down 60%, hit with recent clinical trial setbacks

www.fool.com
| Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? | The Motley Fool
Top performing Nasdaq-100 stocks as of mid-October
Top performing Nasdaq-100 stocks as of mid-October

www.fool.com
| The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going | The Motley Fool
Moderna is up 600% this year and just joined the Nasdaq-100
Moderna is up 600% this year and just joined the Nasdaq-100

www.fool.com
| Meet the New Nasdaq-100 Stock That's Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? | The Motley Fool
Moderna up 500% this year on cancer vaccine trial results, trading well above price targets
Moderna up 500% this year on cancer vaccine trial results, trading well above price targets

www.fool.com
| Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell? | The Motley Fool
Everest Medicines hires former Moderna execs to lead mRNA cancer vaccine research
Everest Medicines hires former Moderna execs to lead mRNA cancer vaccine research

finance.yahoo.com
| Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
Moderna joining the Nasdaq-100 index
Moderna joining the Nasdaq-100 index
Moderna has finally joined the Nasdaq-100 index this week. I am curious if you all think the market is finally giving the credit it deserves for its broader mRNA pipeline beyond just the vaccines. Do you feel the current valuation reflects the potential in their oncology work, or are we just seeing a temporary technical bump?
OpenAI and Anthropic's push for regulation might just be a cost-saving moat
OpenAI and Anthropic's push for regulation might just be a cost-saving moat

www.fool.com
| AI Leaders Want to Slow Down Development | The Motley Fool
